sinc
origin
report
describ
use
adenoassoci
viru
aav
vector
transfer
gene
muscl
kessler
et
al
xiao
et
al
fisher
et
al
recombin
aav
raav
emerg
effici
potenti
nonimmunogen
vector
candid
deliv
therapeut
gene
varieti
tissu
treat
monogen
diseas
poorli
activ
innat
immun
weakli
transduc
dendrit
cell
raav
appear
far
less
immunogen
adenovir
vector
zhang
et
al
zaiss
et
al
mccaffrey
et
al
nevertheless
rapidli
becom
clear
raav
vector
carri
variou
transgen
differ
condit
induc
potent
immun
respons
could
ultim
lead
destruct
transduc
cell
vivo
consecut
disappear
transgen
express
man
et
al
man
et
al
halbert
et
al
brockstedt
et
al
surprisingli
therefor
use
even
propos
genet
vaccin
protocol
aim
elicit
cellular
humor
immun
respons
differ
microorgan
kuck
et
al
du
et
al
primat
human
raav
administr
also
document
elicit
signific
cytotox
cell
respons
direct
viral
well
transgen
exogen
protein
result
destruct
transduc
cell
complet
loss
transgen
express
manno
et
al
mingozzi
et
al
gao
et
al
addit
side
humor
immun
product
neutral
antibodi
target
capsid
protein
may
also
prevent
vector
readministr
acceler
loss
therapeut
protein
format
immun
complex
immun
complex
may
sensit
cellular
immun
respons
enhanc
crosspresent
transgen
protein
antigenpres
cell
apc
therefor
develop
strategi
circumv
immun
respons
facilit
longterm
express
transgen
therapeut
protein
identifi
one
today
main
challeng
translat
raav
vector
clinic
mingozzi
high
b
nayak
herzog
depend
experiment
situat
raavmedi
gene
transfer
either
lead
durabl
transgen
express
convers
rapid
format
neutral
antibodi
andor
destruct
transduc
cell
cytotox
cell
sever
factor
influenc
immun
respons
transgen
protein
encod
raav
vector
identifi
includ
host
speci
rout
administr
vector
dose
immunogen
transgen
protein
inflammatori
statu
host
capsid
serotyp
may
wilson
factor
thought
influenc
immunogen
trigger
innat
immun
cytokin
product
apc
matur
antigen
present
ultim
prime
lymphocyt
function
effector
therefor
idea
dampen
immun
activ
interf
mechan
logic
emerg
aim
induc
shortterm
immunosuppress
avoid
earli
immun
prime
follow
vector
administr
promot
longterm
toler
zaiss
muruv
evalu
two
differ
strategi
inhibit
undesir
immun
activ
follow
muscl
gene
transfer
act
two
differ
checkpoint
immun
respons
ie
cell
prime
function
activ
cell
may
escap
prime
blockad
use
administr
inhibit
substanti
immun
prime
immedi
follow
vector
inject
inde
repres
potent
immunosuppress
fusion
protein
revers
prevent
cell
activ
wallac
et
al
use
clinic
treat
inflammatori
diseas
rheumatoid
arthriti
blueston
et
al
immunomodulatori
action
depend
competit
inhibitori
effect
pathway
therebi
prevent
pivot
costimul
requir
fulli
activ
lymphocyt
salomon
blueston
second
strategi
turn
immunomodulatori
molecul
could
protect
transduc
muscl
fiber
immun
attack
activ
cell
aim
stimul
inhibitori
molecul
express
cell
upon
activ
gene
transfer
ligand
muscl
cell
freeman
et
al
latchman
et
al
ishida
et
al
show
herein
act
two
nonredund
mechan
toler
provid
synergist
effect
prolong
transgen
express
muscl
even
presenc
circul
cytotox
cell
direct
transgen
product
femal
mice
obtain
centr
delevag
janvier
le
genest
saint
isl
franc
mice
week
age
begin
experi
transduct
raav
vector
mice
back
leg
shave
gener
anesthesia
titrat
vector
genom
vg
inject
pb
gastrocnemiu
muscl
indic
vg
mix
vg
raavova
coinject
use
procedur
costimul
blockad
experi
mice
inject
ip
chimerigen
laboratori
dilut
pb
experi
lymphocyt
toler
mice
transfer
condit
recipi
evalu
presenc
antiova
lymphocyt
studi
function
vivo
splenocyt
harvest
individu
mice
treat
day
aavova
without
immunomodulatori
regimen
inject
iv
gyirradi
syngen
recipi
one
day
individu
mous
shave
inject
subcutan
syngen
tumor
cell
express
ova
antigen
known
sensit
vivo
cell
cytotox
prime
anim
moor
et
al
tumor
size
measur
digit
calip
three
time
week
day
tumor
volum
calcul
length
width
length
width
anim
experi
approv
local
institut
ethic
committe
anim
experiment
author
en
animal
de
normandi
raavova
vector
kind
gift
roland
w
herzog
describ
previous
wang
et
al
cdna
encod
mous
clone
use
standard
molecular
biolog
procedur
introduc
plasmid
backbon
digest
ecori
result
express
cassett
flank
aav
serotyp
invert
termin
repeat
itr
contain
cag
promot
combin
cytomegaloviru
earli
enhanc
chicken
promot
chicken
intron
rabbit
polyadenyl
signal
vector
gener
use
standard
helperviru
free
threeplasmid
transient
transfect
method
pseudotyp
either
capsid
protein
vector
purifi
two
cesium
chlorid
gradient
centrifug
dialyz
pb
describ
salvetti
et
al
genom
titer
vector
prepar
assay
dotblot
hybrid
use
probe
detect
cag
cmv
promot
quantif
solubl
ova
sova
concentr
serum
perform
ovaspecif
elisa
microtit
plate
coat
polyclon
rabbit
antiova
antibodi
dilut
raybiotech
bound
sova
detect
use
biotinyl
rabbit
polyclon
antiova
antibodi
dilut
abcam
streptavidinperoxidas
roch
detect
serum
antiova
igg
antibodi
perform
elisa
use
ovaco
microtit
plate
antiova
igg
antibodi
detect
use
biotinyl
polyclon
goat
antimous
igg
reveal
use
mous
extravidin
kit
sigmaaldrich
igg
titer
defin
dilut
yield
half
maximum
optic
densiti
obtain
control
serum
calcul
use
sigmoid
curv
fit
use
graphpad
prism
softwar
analyz
quantiti
ova
dna
ova
mrna
present
transduc
muscl
treat
mice
indic
time
point
realtim
pcr
assay
develop
muscl
collect
mous
kept
dna
rna
extract
perform
use
phenolchloroform
method
rneasi
fibrou
tissu
mini
kit
qiagen
follow
manufactur
instruct
quantif
ova
dna
primer
use
ovaf
aag
cag
gca
gag
agg
tgg
ovar
gaa
tgg
atg
gtc
agc
cct
ggt
gca
ttc
tca
ctc
tga
gtt
gca
gac
aga
gct
gat
ttc
cta
tgt
reaction
mixtur
faststart
univers
sybr
green
master
mix
roch
use
final
volum
ova
primer
use
nm
primer
nm
approxim
ng
dna
ad
volum
alway
set
duplic
qpcr
perform
follow
condit
min
hotstart
denatur
amplif
cycl
frontier
microbiolog
microbi
immunolog
melt
temperatur
final
doublestrand
dna
product
determin
gradual
heat
min
qpcr
perform
steponeplu
realtim
pcr
system
appli
biosystem
correspond
softwar
absolut
amount
ova
amplicon
arbitrari
unit
determin
use
serial
dilut
paavcmvova
plasmid
plasmid
standard
data
express
ratio
fix
pbsinject
control
mice
quantif
ova
mrna
ng
total
rna
revers
transcrib
use
iscript
dna
synthesi
kit
biorad
cdna
subject
realtim
pcr
amplif
use
ova
primer
aag
atc
tgg
cac
cac
acc
ttc
ttt
tca
cgg
ttg
gcc
tta
primer
reaction
mixtur
faststart
univers
sybr
green
master
mix
roch
use
final
volum
ova
primer
use
nm
primer
nm
qpcr
program
abovedescrib
condit
use
absolut
amount
ova
mrna
sampl
normal
mrna
amount
arbitrari
unit
determin
use
serial
dilut
paavcmvova
plasmid
purifi
pcr
product
fluoresc
label
monoclon
antibodi
mab
unlabel
antibodi
purchas
ebiosci
peconjug
b
ova
pentam
use
detect
cell
specif
recogn
immunodomin
ovaderiv
siinfekl
peptid
use
manufactur
protocol
proimmun
flow
cytometri
measur
singl
cell
suspens
deriv
lymph
node
spleen
blood
sampl
perform
use
standard
procedur
acquir
facscanto
bd
bioscienc
instrument
flow
cytometri
analys
perform
use
flowjo
softwar
tree
star
enzymelink
immunospot
elispot
assay
perform
follow
instruct
manufactur
diaclon
briefli
pvdf
membran
plate
coat
captur
antibodi
mous
block
skim
milk
solut
prepar
pb
splenocyt
per
well
cultur
vitro
h
presenc
siinfekl
peptid
plate
reveal
incub
antimous
detect
antibodi
coupl
biotin
follow
streptavidinalkalin
phosphatas
conjug
exposur
readytous
solut
nitroblu
tetrazolium
nbt
indolyphosph
bcip
chromogen
develop
plate
analyz
elispot
plate
reader
dedic
immunospot
softwar
ctl
result
express
mean
sem
signific
assess
nonparametr
oneway
anova
kruskalw
test
use
graphpad
prism
softwar
result
consid
statist
signific
p
valu
inferior
use
administr
model
gene
therapi
set
transgen
encod
highli
immunogen
secret
protein
first
evalu
capac
vector
transduc
muscl
cell
upon
direct
im
inject
inject
viral
genom
vg
similarli
result
effici
transduct
attest
detect
ova
dna
mrna
inject
muscl
quantifi
qpcr
qrtpcr
respect
figur
signific
differ
found
compar
transduct
effici
condit
transgen
express
muscl
found
high
earli
transduct
rapidli
declin
time
suggest
occurr
immun
respons
transduc
cell
figur
investig
point
quantifi
cellular
humor
immun
respons
direct
xenogen
ova
transgen
product
flow
cytometri
elisa
stain
mhci
pentam
present
immunodomin
ovaderiv
siinfekl
peptid
design
hereaft
b
ova
pentam
allow
monitor
expans
lymphocyt
spleen
drain
lymph
node
raavova
challeng
anim
analysi
reveal
inject
gastrocnemiu
muscl
induc
robust
expans
antiova
lymphocyt
figur
c
interestingli
kinet
intens
cell
prime
found
differ
compar
cell
harvest
drain
lymph
node
spleen
lymph
node
drain
inject
muscl
antiova
cell
expand
earli
aav
challeng
reach
around
cell
compart
day
postinject
figur
left
panel
contrast
analyz
splenocyt
antiova
cell
found
reach
total
subset
day
im
aav
inject
figur
right
panel
result
consist
model
local
cellular
immun
respons
measur
drain
lymph
node
would
induc
raav
leakag
inject
muscl
consequ
transduct
nonmuscl
cell
dendrit
cell
shown
xin
et
al
lu
song
instanc
system
respons
detect
spleen
would
rather
reflect
system
immun
direct
circul
sova
protein
produc
transduc
muscl
cell
interpret
support
kinet
sova
apparit
antibodi
product
figur
inde
serum
aavtreat
mice
sova
reach
maximum
day
postinject
rapidli
declin
thereaft
figur
green
curv
consist
antiova
igg
appear
day
aav
im
inject
correl
disappear
sova
serum
day
figur
blue
curv
latter
probabl
reflect
vivo
clearanc
sova
follow
format
antigenantibodi
immun
complex
although
complet
rule
antiova
igg
antibodi
may
mask
ova
epitop
immunoassay
togeth
data
reveal
im
inject
wwwfrontiersinorg
raav
encod
sova
strongli
immunogen
provid
mous
model
suit
stringent
evalu
efficaci
toler
induct
protocol
investig
possibl
block
immun
respons
direct
transgen
product
two
distinct
immunomodulatori
strategi
one
block
lymphocyt
prime
ie
inhibit
function
lymphocyt
target
transduc
muscl
fiber
ie
activ
pathway
muscl
gene
transfer
ligand
inde
previous
shown
transgen
mice
express
ova
neoautoantigen
muscl
toler
transgen
antiova
cell
upregul
suggest
play
role
induct
toler
skelet
muscleexpress
ag
calbo
et
al
expect
antiova
cell
respons
follow
im
inject
figur
c
accompani
upregul
cell
exhibit
activ
hi
phenotyp
figur
activ
cell
express
ligand
inhibit
activ
function
gener
vector
first
verifi
abl
effici
transduc
hek
cell
vitro
figur
expect
consequ
inject
vector
im
prevent
cell
prime
rather
inhibit
cytotox
activ
cell
direct
muscleexpress
transgen
protein
investig
vivo
immunomodulatori
potenti
either
administ
ip
coinject
im
time
monitor
cellular
humor
immun
respons
day
result
show
even
singl
dose
effici
complet
prevent
prime
antiova
cell
figur
left
panel
apparit
antiova
igg
serum
treat
anim
figur
middl
panel
accordingli
immunosuppress
treatment
allow
sustain
sova
product
could
assay
serum
day
wherea
undetect
control
figur
right
panel
conclud
data
transient
immunosuppress
singl
dose
effici
prevent
prime
cellular
humor
respons
earli
time
point
aav
transduct
contrast
despit
slight
statist
signific
tendenc
reduc
immun
respons
coinject
fail
provid
effect
immun
prime
figur
left
middl
panel
also
treatment
allow
persist
sova
serum
agreement
signific
amount
antiova
igg
detect
serum
anim
figur
expect
result
confirm
local
transduct
muscl
cell
interfer
system
immun
prime
sova
sinc
activ
pathway
anticip
regul
cell
function
rather
prime
analyz
presenc
ova
dna
mrna
muscl
day
differ
group
treat
mice
qpcr
qrtpcr
respect
confirm
suppress
immun
prime
promot
persist
transduc
cell
vivo
measur
detect
significantli
higher
level
ova
dna
mrna
muscl
treat
anim
figur
contrast
inject
frontier
microbiolog
microbi
immunolog
figur
vg
gastrocnemiu
muscl
day
splenic
cell
analyz
day
flow
cytometri
express
b
vector
design
produc
test
capac
transduc
cell
vitro
cell
analyz
flow
cytometri
day
transduct
dilut
concentr
viru
stock
control
correspond
unmanipul
parent
cell
stain
antibodi
green
histogram
c
immunosuppress
potenti
evalu
vivo
mice
inject
vg
gastrocnemiu
muscl
receiv
coinject
vg
inject
contemporan
ip
rout
blood
sampl
collect
day
later
analyz
percentag
antiova
cell
level
antiova
igg
presenc
sova
serum
gastrocnemiu
muscl
collect
day
ova
dna
mrna
quantifi
qpcr
qrtpcr
significantli
improv
transgen
persist
set
line
promin
system
immun
respons
detect
day
figur
wherea
singl
dose
effici
suppress
system
immun
respons
day
figur
b
left
panel
case
monitor
immun
respons
day
inde
antiova
cell
expans
well
antiova
igg
immun
respons
readili
detect
day
mice
receiv
day
figur
b
therefor
earli
suppress
immun
prime
singl
dose
suffici
perman
wipe
immun
respons
transgen
product
experiment
condit
instead
continu
product
sova
transduc
muscl
cell
sensit
immun
respons
later
time
point
clear
circul
treat
mice
next
test
whether
could
synerg
improv
transgen
toler
later
time
point
initi
monotherapi
evid
effici
alon
complet
block
immun
sensit
sova
combin
strategi
may
inde
target
two
nonredund
mechan
immunomodul
act
wwwfrontiersinorg
either
apc
side
target
tissu
side
test
possibl
group
mice
transduc
im
also
receiv
time
either
im
ip
combin
therapi
evalu
cellular
humor
immun
respons
differ
time
point
final
evalu
persist
transduc
muscl
cell
quantif
ova
dna
mrna
day
figur
remark
wherea
alon
ineffici
coadminist
day
significantli
improv
transgen
persist
measur
quantif
ova
dna
qpcr
figur
left
panel
accordingli
mrna
analysi
qrtpcr
day
reveal
sustain
transcript
transgen
muscl
figur
right
panel
note
appear
equal
effect
provid
effect
combin
importantli
protect
effect
occur
set
neither
alon
test
combin
therapi
could
block
immun
respons
day
figur
b
attest
presenc
function
antiova
cytotox
cell
day
time
point
pentam
stain
sensit
enough
detect
antiova
cell
shown
analyz
elispot
capac
cell
secret
stimul
ovaderiv
immunodomin
siinfekl
peptid
assay
reveal
presenc
low
number
function
antiova
cell
three
group
anim
receiv
without
wherea
assay
neg
mice
receiv
raavova
strongli
posit
receiv
raavova
absenc
immunoregulatori
adjuv
therapi
figur
definit
demonstr
cell
function
vivo
perform
adopt
transfer
experi
nonleth
irradi
syngen
recipi
inocul
ovabear
tumor
cell
wherea
tumor
rapidli
develop
recipi
receiv
cell
control
mice
receiv
pb
recipi
mice
receiv
lymphocyt
inject
donor
rapidli
develop
antitumor
immun
respons
result
complet
tumor
reject
figur
agreement
lower
number
antiova
cell
detect
elispot
recipi
mice
receiv
immun
cell
donor
treat
combin
plu
therapi
react
slight
delay
also
also
capabl
effici
control
tumor
growth
figur
togeth
result
indic
cytotox
activ
transgen
product
specif
cell
escap
costimul
blockad
function
block
aavmedi
gene
transfer
ligand
muscl
tissu
remain
capabl
reject
tumor
cell
gene
therapi
muscular
dystrophi
monogen
diseas
aim
achiev
longterm
express
function
form
otherwis
defici
gene
target
tissu
context
product
therapeut
gene
structur
differ
abnorm
absent
counterpart
consequ
view
nonself
immun
system
addit
signal
viral
vector
may
strengthen
advers
innat
adapt
immun
reaction
transgen
product
vector
target
antivir
preexist
acquir
immun
although
presenc
natur
epitop
nonmut
region
protein
occasion
occurr
mutat
revers
minut
popul
patient
cell
klein
et
al
may
yield
level
immunolog
toler
remain
acquir
immun
transgen
product
still
repres
one
major
obstacl
success
gene
therapi
provid
proof
principl
combin
immunoregulatori
therapi
target
two
nonredund
checkpoint
immun
respons
ie
prime
effector
function
promot
persist
transduc
target
cell
transgen
transcript
thereof
even
cytotox
cell
escap
initi
control
first
strategi
blockad
adapt
immun
obvious
target
costimul
pathway
therefor
provid
earli
control
lymphocyt
prime
wherea
sever
costimulatori
pathway
identifi
cell
costimul
apc
express
molecul
famili
clearli
promin
inde
signal
strongli
enhanc
cell
prolifer
surviv
cytokin
product
prevent
induct
anergi
tcrmediat
activ
bois
et
al
consequ
antibodi
inhibit
cell
prime
genet
engin
cell
strongli
impair
capac
expand
green
et
al
salomon
blueston
cell
activ
also
promot
upregul
neg
regul
anoth
ligand
molecul
transmit
inhibitori
signal
regul
activ
cell
provid
key
homeostat
mechan
immun
respons
fife
blueston
one
earli
strike
evid
key
role
molecul
anim
rapidli
die
figur
detect
antiova
cell
anim
treat
combin
therapi
seven
mice
per
group
inject
vg
gastrocnemiu
muscl
day
receiv
time
combin
therapi
figur
splenocyt
harvest
day
analyz
presenc
lymphocyt
capabl
respond
ova
antigen
splenocyt
analyz
elispot
describ
section
materi
method
capac
secret
vitro
restimul
ovaderiv
immunodomin
siinfekl
peptid
b
splenocyt
mice
also
adopt
transfer
gyirradi
syngen
mice
inocul
day
ovabear
tumor
cell
capac
transfer
lymphocyt
reject
tumor
monitor
three
time
per
week
measur
tumor
size
digit
calip
wwwfrontiersinorg
massiv
lymphoprolif
syndrom
dysregul
immun
waterhous
et
al
one
conveni
way
pharmacolog
block
costimul
pathway
use
solubl
ligand
fusion
protein
prevent
interact
molecul
activ
cell
therefor
provid
strong
earli
inhibit
cell
prime
june
et
al
lenschow
et
al
larsen
et
al
may
also
induc
neg
signal
apc
side
induct
ido
catalys
product
inhibitori
kynurenin
tryptophan
grohmann
et
al
may
also
possibl
provid
level
apc
deplet
vivo
although
aspect
poorli
document
critic
depend
form
use
importantli
clinic
avail
treatment
diseas
rheumatoid
arthriti
dumont
thu
reason
propos
evalu
field
gene
therapi
inde
experiment
evid
combin
monoclon
antibodi
context
gene
therapi
block
immun
respons
allow
vector
readministr
mous
halbert
et
al
lorain
et
al
difficult
weight
rel
role
experi
plausibl
hypothesi
provid
strongest
immunoregulatori
contribut
sinc
alon
report
less
effici
similar
experiment
condit
man
et
al
result
report
herein
consist
earlier
report
provid
definit
evid
alon
effici
transient
block
antitransgen
cell
prime
one
concern
use
gene
therapi
discontinu
treatment
expos
patient
immun
transgen
product
present
result
illustr
point
sinc
initi
effici
block
antiova
cellular
humor
respons
sustain
sova
product
final
elicit
undesir
respons
probabl
clear
circul
experiment
condit
purpos
design
model
situat
immun
respons
escap
initi
immunoregulatori
regimen
order
evalu
second
strategi
could
provid
addit
protect
transduc
cell
ie
gene
therapi
pathway
recent
identifi
neg
regul
immun
immunoreceptor
also
member
famili
upon
interact
either
one
two
ligand
downmodul
tcr
signal
reduc
cytokin
product
affect
cell
surviv
recruit
tyrosin
phosphatas
therebi
dampen
akt
pathway
francisco
et
al
balbc
mice
defici
lead
spontan
develop
lethal
autoimmun
cardiomyopathi
diseas
mediat
autoantibodi
direct
cardiac
muscl
autoantigen
troponin
okazaki
et
al
henc
control
physiolog
toler
muscl
autoantigen
also
recent
shown
regul
cellmedi
muscl
injuri
mous
model
myocard
grabi
et
al
sever
depend
mechan
may
act
synergist
induc
effect
effector
cell
blockad
contribut
toler
induct
mention
earlier
engag
surfac
cell
known
significantli
inhibit
tcr
signal
therebi
prevent
cell
activ
cytokin
product
addit
mechan
recent
shown
potent
induc
adapt
treg
inde
express
dendrit
cell
subset
play
import
role
convers
naiv
lymphocyt
toward
regulatori
cell
wang
et
al
thu
engag
cell
could
induc
cellintrins
toler
block
tcr
signal
well
domin
form
immunolog
toler
promot
emerg
adapt
treg
note
manipul
axi
also
use
tumor
cell
toler
surround
lymphocyt
inde
express
surfac
malign
cell
suggest
repres
subvers
strategi
use
tumor
escap
immunosurveil
thu
believ
upregul
express
surfac
muscl
cell
mean
gene
transfer
abl
induc
toler
immun
system
prevent
cytotox
activ
lymphocyt
howev
gene
transfer
alon
suffici
model
prevent
immun
respons
direct
transduc
muscl
fiber
figur
suggest
muscl
express
ie
distanc
lymphoid
compart
probabl
capabl
induc
suffici
adapt
treg
anoth
explan
would
express
muscl
effect
block
fulli
activ
cell
receiv
normal
costimulatori
signal
ie
absenc
coadministr
interpret
would
line
find
inhibitori
pathway
could
overcom
costimulatori
ligat
presenc
freeman
et
al
latchman
et
al
carter
et
al
ishida
et
al
henc
use
block
earli
costimulatori
signal
may
creat
favor
condit
escap
cell
could
becom
sensit
strengthen
notion
signal
repres
two
distinct
pathway
act
synergist
maintain
toler
fife
blueston
shown
herein
neither
alon
combin
therapi
could
block
immun
respons
day
figur
result
thu
compat
notion
use
combin
complet
inhibit
immun
prime
sova
probabl
occur
distanc
site
transduct
eg
spleen
andor
lymph
node
instead
provid
addit
protect
disarm
lymphocyt
within
target
tissu
argu
prime
cell
direct
transgen
product
may
somehow
defect
raavmedi
gene
transfer
lin
et
al
b
howev
experiment
set
transduc
muscl
fiber
progress
disappear
absenc
immunoregulatori
treatment
figur
show
even
alon
combin
therapi
antiova
immun
respons
evidenc
elispot
assay
vivo
model
tumor
reject
upon
adopt
transfer
cell
recipi
anim
figur
henc
forc
upregul
ligand
muscl
cell
yield
level
protect
transduc
cell
cytotox
assault
frontier
microbiolog
microbi
immunolog
circul
antiova
lymphocyt
provid
combin
therapi
mean
prolong
transgen
persist
transcript
therefor
plu
combin
therapi
repres
candid
approach
circumv
bottleneck
immun
respons
direct
toward
transgen
product
may
deserv
investig
nonsecret
transgen
protein
model
larger
anim
sahil
adriouch
design
research
perform
experi
analyz
data
cowrot
manuscript
anna
salvetti
olivi
boyer
design
research
cowrot
manuscript
emili
franck
laurent
drouot
carol
bonneau
nelli
jolinon
perform
experi
